Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors

被引:17
作者
Giovannoni, Maria P. [1 ]
Cesari, Nicoletta [1 ]
Graziano, Alessia [1 ]
Vergelli, Claudia [1 ]
Biancalani, Claudio [1 ]
Biagini, Pierfrancesco [1 ]
Dal Piaz, Vittorio [1 ]
机构
[1] Dipartimento Sci Farmaceut, I-50019 Florence, Italy
关键词
pyrrolopyridazinones; PDE4; subtypes; inhibitors; selectivity; TNF alpha;
D O I
10.1080/14756360601114700
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of pyrrolo [2,3-d] pyridazinones was synthesized and tested for their inhibitory activity on PDE4 subtypes A, B and D and selectivity toward Rolipram high affinity binding site (HARBS). New agents with interesting profile were reported; in particular compound 9e showed a good PDE4 subtype selectivity, being 8 times more potent IC50 = 0.32 mu M) for PDE4B (anti-inflammatory) than for PDE4D (IC50 = 2.5 mu M), generally considered the subtype responsible for emesis. Moreover the ratio HARBS/PDE4B was particularly favourable for 9e (147), suggesting that the best arranged groups around the pyrrolopyridazinone core are an isopropyl at position-1, an ethoxycarbonyl at position-2, together with an ethyl group at position-6. For compounds 8 and 15a the ability to inhibit TNF alpha production in PBMC was evaluated and the results are consistent with their PDE4 inhibitory activity.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 39 条
[1]   THE ACYLATION OF KETONES WITH ALIPHATIC ANHYDRIDES BY MEANS OF BORON TRIFLUORIDE - SYNTHESIS OF BETA-DIKETONES [J].
ADAMS, JT ;
HAUSER, CR .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1945, 67 (02) :284-286
[2]   CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors [J].
Alexander, RP ;
Warrellow, GJ ;
Eaton, MAW ;
Boyd, EC ;
Head, JC ;
Porter, JR ;
Brown, JA ;
Reuberson, JT ;
Hutchinson, B ;
Turner, P ;
Boyce, B ;
Barnes, D ;
Mason, B ;
Cannell, A ;
Taylor, RJ ;
Zomaya, A ;
Millican, A ;
Leonard, J ;
Morphy, R ;
Wales, M ;
Perry, M ;
Allen, RA ;
Gozzard, N ;
Hughes, B ;
Higgs, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (11) :1451-1456
[3]  
Aoki M, 2000, J PHARMACOL EXP THER, V295, P255
[4]  
Aoki M, 2001, J PHARMACOL EXP THER, V298, P1142
[5]  
Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420
[6]   Efficacy and safety of roflumilast in the treatment of asthma [J].
Bateman, Eric D. ;
Izquierdo, Jose Luis ;
Harnest, Ulf ;
Hofbauer, Peter ;
Magyar, Pal ;
Schinid-Wirlitsch, Christine ;
Leichtl, Stefan ;
Bredenbroeker, Dirk .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (05) :679-686
[7]   EOSINOPHIL INFLAMMATION IN ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
VIGNOLA, AM ;
LACOSTE, JY ;
MICHEL, FB .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (05) :S33-S38
[8]   INHIBITION OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE BY DERIVATIVES OF 1,3-BIS(CYCLOPROPYLMETHYL)XANTHINE [J].
BUCKLE, DR ;
ARCH, JRS ;
CONOLLY, BJ ;
FENWICK, AE ;
FOSTER, KA ;
MURRAY, KJ ;
READSHAW, SA ;
SMALLRIDGE, M ;
SMITH, DG .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (04) :476-485
[9]   Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs [J].
Burnouf, C ;
Pruniaux, MP .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (14) :1255-1296
[10]   1,4-cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma [J].
Christensen, SB ;
Guider, A ;
Forster, CJ ;
Gleason, JG ;
Bender, PE ;
Karpinski, JM ;
DeWolf, WE ;
Barnette, MS ;
Underwood, DC ;
Griswold, DE ;
Cieslinski, LB ;
Burman, M ;
Bochnowicz, S ;
Osborn, RR ;
Manning, CD ;
Grous, M ;
Hillegas, LM ;
Bartus, JO ;
Ryan, MD ;
Eggleston, DS ;
Haltiwanger, RC ;
Torphy, TJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (06) :821-835